More than a decade af­ter its ac­cel­er­at­ed ap­proval, vot­ing ques­tions set for pre­ma­ture birth drug's with­draw­al hear­ing

First ap­proved in 2011 un­der the ac­cel­er­at­ed ap­proval path­way to re­duce the risk of pre­ma­ture births, Co­vis Phar­ma’s Mak­e­na flunked its con­fir­ma­to­ry study, fail­ing to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER